Guardant Health and Zephyr AI have partnered to advance the discovery of novel cancer biomarkers, as more precise tumour ...

The United States Prostate Cancer Biomarkers Market is projected to grow from $1.48 billion in 2024 to $3.54 billion by 2033, ...

Oncology-focused biotech company Guardant Health is partnering with AI drug development company Zephyr AI to combine AI and ...

Adelaide researchers have identified a promising new biomarker and treatment target for ovarian cancer that could markedly ...

Guardant Health (Nasdaq: GH), a leading precision oncology company, and Zephyr AI, a leader in precision medicine harnessing ...

The researchers argue that the integration of explainable AI into clinical decision-making pipelines could reshape cancer ...

Circulating tumor DNA (ctDNA) is a promising biomarker for monitoring treatment response and progression-free survival in ...

Biomarkers are pivotal for confirming diagnoses, predicting disease progression, and tailoring therapeutic modalities. Recent ...

Cancer treatment is no longer limited to standard protocols . The same drug, given in the same way, does not work for every ...

Researchers identify FGFR4, FLT1, and WNT5A as key biomarkers and suggest dovitinib and nintedanib as new targeted therapies ...

Adding the antiangiogenic drug to standard care does not extend overall survival among patients with metastatic esophageal ...

Three presentations at ESMO 2025 will demonstrate Lunit SCOPE IO’s value in predicting immunotherapy response in colorectal, ...